The results suggested that patients in the low AIGS group exhibited a higher immune response rate (Fig. 7D), higher IPS score (Fig. 7E), and a superior anti‐PD‐1 and CTLA‐4 immunotherapy efficacy (Fig. 7F), indicating the powerful stability of AIGS in predicting immune response for BLCA. The gene discussed is CTLA4; the disease is bladder transitional cell carcinoma.